Enjoji M, Yamaguchi K, Nakamuta M, Nakashima M, Kotoh K, Tanaka M, Nawata H, Watanabe T
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Dig Liver Dis. 2004 Sep;36(9):622-7. doi: 10.1016/j.dld.2004.04.006.
We have demonstrated immunohistochemically that RCAS 1 antigen is expressed in biliary neoplasms. Serum RCAS 1 levels are also elevated in a high percentage of patients with intra-hepatic cholangiocarcinoma.
The study was designed to determine whether serum levels of RCAS1 are of clinical significance as a tumour marker for biliary tract tumour, in comparison to CA19-9.
In 38 patients with biliary carcinoma (gallbladder carcinoma, extra-hepatic and intra-hepatic cholangiocarcinoma and ampullary carcinoma), we measured serum RCAS1 and CA19-9 levels. For control, serum samples from patients with benign biliary disease and healthy volunteers were also examined.
We established a threshold value for RCAS1 of 17.5 U/ml, which permitted discrimination between malignant and non-malignant biliary diseases. In comparison to CA 19-9, serum RCAS1 was more sensitive and specific for malignancy, and was not influenced by cholestasis. RCAS1 levels varied with respect to the disease course and the effect of clinical treatment.
Serum RCAS1 appears to be valuable as a diagnostic index for biliary carcinomas, as well as for evaluating the progression of cancers during therapy. We speculate that RCAS1 is a clinically more significant serum marker for biliary neoplasms than CA19-9.
我们通过免疫组化法证实，RCAS 1抗原在胆管肿瘤中表达。肝内胆管癌患者中，血清RCAS 1水平也有很高比例升高。
本研究旨在确定与CA19-9相比，血清RCAS1水平作为胆道肿瘤肿瘤标志物是否具有临床意义。
我们检测了38例胆管癌（胆囊癌、肝外和肝内胆管癌以及壶腹癌）患者的血清RCAS1和CA19-9水平。作为对照，还检测了良性胆道疾病患者和健康志愿者的血清样本。
我们确定RCAS1的阈值为17.5 U/ml，这有助于区分恶性和非恶性胆道疾病。与CA 19-9相比，血清RCAS1对恶性肿瘤更敏感、更具特异性，且不受胆汁淤积影响。RCAS1水平随病程和临床治疗效果而变化。
血清RCAS1似乎是胆管癌的有价值诊断指标，也可用于评估治疗期间癌症的进展。我们推测，RCAS1在临床上是比CA19-9更重要的胆管肿瘤血清标志物。
